FDA Approval for Low-Grade Serous Ovarian Cancer: A New Era in Treatment
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
FDA Approval for Low-Grade Serous Ovarian Cancer: A New Era in Treatment
-
Narrated by:
-
By:
About this listen
Discover a groundbreaking advancement in ovarian cancer care in this episode of Teal Talk – An Ovarian Cancer Podcast! Leading experts Dr. Deborah Richardson and Dr. Rachel Grisham join the discussion to explore the FDA approval of the first targeted treatment for recurrent low-grade serous ovarian cancer (LGSOC) with KRAS mutations. Whether you're a patient, caregiver, or healthcare provider, this episode offers vital insights into the future of ovarian cancer treatment.
💬 Like, comment, and subscribe for more vital discussions about ovarian cancer.
📋 Survey Link: https://bit.ly/tealtalksurvey
👉 For more information about ovarian cancer and the National Ovarian Cancer Coalition, visit https://ovarian.org.
This podcast is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always talk to a qualified healthcare provider if you have questions about your health. The podcast is created independently by the National Ovarian Cancer Coalition and is not influenced by sponsors or outside groups.